The Role of Bronchiectasis and COPD as Risk Factors for MAC Lung Disease
Critical Advances in Disease Stratification and Recent International Guidelines for Antimicrobial Management
Patient Identification, Selection, and Timing of Antimicrobial Treatment in the Context of Year 2020 ERS/ATS/ESCMID/IDSA Guideline-Based Therapy for MAC Lung DiseaseNew Guidance for Treatment of High Risk and Refractory Disease
Optimizing Management of MAC Lung Disease with Guideline-Based TherapyCurrent, Evidence-Based Recommendations and Applying the Year 2020 ATS/IDSA/ERS/ESCMID Guidelines and Treatment Plans to the Front Lines of Patient Care for MAC Pulmonary Disease
From Clinical Suspicion and Co-Morbid Risk Factors to Diagnostic Confirmation of MAC Lung DiseaseThe Critical Role of Bronchiectasis, COPD, and TB as Risk Factors for MAC Lung Disease and Implications for Treatment.
Evidence for Prompt, Intensive Intervention in Risk Appropriate Patients with MAC Lung DiseasePractical, Real World Application of Guidelines at the Front Lines of Patient Care for MAC Pulmonary Disease
From Landmark Trials to Evidence-Based Therapy for Resistant, Refractory, High Risk and/or Challenging Patients with MAC Lung InfectionThe Role, Safety, Indications, Evidence, and Efficacy of Novel, Inhaled Antimicrobial Formulations
Real World Case Management: Evaluating and Managing Patients with Advanced MAC Lung Disease/Refractory FeaturesFocus on Indications for and Optimizing Regimen Adherence with Novel Inhaled Antimicrobial Formulations
Method of Physician Participation Utilized in Learning Process
There are no fees for participating and receiving CME credit for this activity. During the period September 5, 2021 through September 5, 2023, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view activity, totaling 1.5 hours, to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out CME certificate.
Estimated Time to Complete Educational Activity
1.5 hours. Physicians must study the enduring activity, and are expected to view every segment to successfully complete the activity and earn CME credit.
In this web-based program, physicians will learn how recent developments in basic and clinical research have helped to advance the understanding and management of non-tubercular mycobacterial (NTM) pulmonary infection with mycobacterium avium complex (MAC).
September 5, 2021
September 5, 2023
This complimentary CME educational activity is designed for all healthcare providers (HCPs) involved in developing, delivering, consulting, and monitoring care for patients with non-tubercular mycobacterial (NTM) pulmonary infection with mycobacterium avium complex (MAC), including infectious disease specialists, pulmonary medicine specialists, and related clinicians.
Participation in this activity is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.
This activity is supported by an independent medical education grant from Insmed.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Massachusetts Chan Medical School and CMEducation Resources, LLC. The University of Massachusetts Chan Medical School is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Massachusetts Chan Medical School, Office of Continuing Medical Education designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Policy on Faculty & Provider Disclosure
It is the policy of the University of Massachusetts Chan Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Chan Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.
Program Faculty and Disclosure
Christoph Lange, MD – Program Co-Chair
Medical Director/Clinical Director
Research Center Borstel
Speaker's bureau: Cellestis, Oxford Immunotech
Consultant: Oxford Immunotech
Charles L. Daley, MD – Program Co-Chair
Chief, Division of Mycobacterial and Respiratory Infections
Professor, Department of Medicine
National Jewish Health
Denver, Colorado, USA
Advisory board: Insmed, Spero Pharmaceuticals, Paratek, Matinas, AN2
Industry and investigator-initiated research: Insmed, Spero Pharmaceuticals, Beyond Air
Stefano Aliberti, MD
Associate Professor in Respiratory Medicine
University of Milan
Policlinico University Hospital
Chair, Italian Registry on Non-Tuberculous Mycobacteria (IRENE)
Consulting: Bayer Healthcare, Grifols, AstraZeneca, Zambon, Chiesi, Insmed,
GlaxoSmithKline, Menarini, ZetaCube Srl
Grants: Insmed, Fisher & Paykel
Rachel Thomson, MD
Director, Mycobacterial Diseases
Gallipoli Medical Research Institute
University of Queensland
Brisbane, QLD, Australia
Nothing to disclose
Program Managers and Web Editor Disclosure
Program Managers Gideon Bosker, MD and Denise Leary have nothing to disclose.
Upon completion of this activity, participants will be able to:
- Understand and discuss the epidemiology and disease burden for NTM-PD based on regional prevalence, susceptible populations, and strategies for confirming the diagnosis of NTM-PD
- Outline the burden of NTM-PD for patients and the healthcare system, especially in regions with high disease burden and poor recognition of this challenging condition
- Compare and differentiate the mechanism of action and delivery systems of different antimicrobial formulations and how these MOA will affect microbial conversion and eradication in NTM-PD
- Detail the risk factors for and clinical presentation of NTM-PD, and initial guideline-based therapy (GBT)
- Evaluate and deploy national (ACCP, ATS, BTS, and IDSA) guideline-based treatment (GBT) and recommendations for the diagnosis, assessment, and treatment of NTM, especially refractory, non-converting NTM-PD
Hardware and Software Requirements:
To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.
When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:
·We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
·For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
·We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
·If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.